FDA grants accelerated approval to new treatment for advance
The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test....

http://satprnews.com/2017/01/22/fda-grants-accelerated-approval-to-new-treatment-for-advanced-ovarian-cancer-2/
Like
Comment
Share